Cibus, Inc.

AI-generated fair value estimate for this company.

Method: Probability-weighted scenario value (DCF not appropriate given disclosed going-concern doubt): 70% probability of a distress/heavily-dilutive-financing scenario (~$0.10/share residual value) and 30% probability of a successful-financing scenario that preserves option value on the EU-approved gene-edited trait licensing pipeline (~$3.50/share), weighted to $1.12/share; based on $20.4M cash, ~2 quarters of disclosed runway, and 76.43M shares outstanding.

Reasoning: Cibus's own Q2 2026 10-Q discloses 'substantial doubt about the Company's ability to continue as a going concern' with only about two quarters of cash runway, so a standard multi-year growth DCF would be misleading; a probability-weighted scenario approach that explicitly prices in a high chance of severe dilution or failure, against a smaller chance that the recent EU regulatory win on gene-edited crops lets the company refinance and realize its pipeline's value, better reflects the real near-term risk.